Textbook of Personalized Medicine - Second Edition [2015]

345 mediator of acquired resistance to EGFR blockade and that these mutations can be detected in a noninvasive manner. A second ...

346 outcomes and the potential for cancer recurrence in patients with HCC and to iden- tify differing subgroups of patients wher ...

347 Crizotinib for Personalized Management of NSCLC Crizotinib (Pfi zer’s Xalkori) is an orally available small molecule that bl ...

348 response. The molecular mechanisms underlying sensitivity to gefi tinib are unknown. It was considered to be a targeted ther ...

349 whereas cetuximab has little effect on the mutant signal, evidently because it strikes at a different part of the EGFR molec ...

350 In another approach to this problem, serum collected from NSCLC patients before treatment with gefi tinib or erlotinib were ...

351 cascades, mediators of acquired resistance must be elucidated for each disease separately in the context of treatment. Patie ...

352 Personalized Therapy of NSCLC Based on KIF5B/RET Fusion Oncogene Although several studies have reported genomic driver mutat ...

353 prognosis group (cathepsin D, ENO1, and VDAC1) to confi rm that the proteins indeed originated from the tumor and not from a ...

354 Selecting Therapy of Cancer Arising from Respiratory Papillomatosis In a case of recurrent respiratory papillomatosis with p ...

355 Testing for Prognosis of Lung Cancer A substantial number of studies have reported the development of gene expression- based ...

356 potential, such as the presence of ulceration or mitoses. The genetic characterization of primary tumors as well as heredita ...

357 certain BRAF mutations. Simultaneously, the agency approved BioMérieux’s THxID-BRAF companion diagnostic, a real-time PCR as ...

358 Personalized Management of Pancreatic Cancer Pancreatic cancer is the fourth leading cause of death from cancer in the US; a ...

359 pancreatic cancer, sensitive and specifi c biomarkers are also required. Extensive genomics/transcriptomics and proteomics s ...

360 routine contrast-enhanced CT scans of individual human PDAC tumors (Koay et al. 2014 ). Additionally, gemcitabine infusion d ...

361 with PrCa risk, described by rs117576373. Additional genotyping, conditional regression and haplotype analyses indicated tha ...

362 randomized phase II trial using docetaxel and thalidomide versus docetaxel alone were genotyped using the Affymetrix DMET 1. ...

363 prostatectomy. Because the patient outcome depends on the level of PSA, this ultrasensitive assay enables: (1) informing pat ...

364 Personalized Peptide Vaccine for Prostate Cancer HER2/neu protein is also expressed in prostate cancer. High-risk prostate c ...